Suite of push and pull incentives to support antimicrobial innovation

Too few antibiotics in thePIPELINEAs of May 2017,51 antibioticsand 11 biologicalswere in the clinicalpipeline.Only 5 are expectedto reach the market

Growing antimicrobial RESISTANCE

Grants Pipeline coordinators Market Entry Rewards

ReimbursementReforms

Transferable Market Exclusivity

10 mil. people are expected to die from infections caused by resistant bacteria by

2050 globally. Already there are 25,000

deaths in the EU alone every year.

25,000deaths/year

700,000 deaths/year

globaly

Challenges of applyingthe traditional

economic modelAntibiotics are meant

to be used appropriately and

responsibly.

BASICSCIENCE

PHASE I CLINICAL

TRIAL

PRECLINICAL DEVELOPMENT

PHASE III CLINICAL

TRIAL

PHASE II CLINICAL

TRIALMARKETING

AUTHORISATIONPUSH

INCENTIVES

Non-repayable funds for R&D given to academic institutions, companies and others

Governmental or non-pro�t organisations that closely track the antibiotic pipeline, identify gaps, and actively support R&D projects both �nancially and technically to �ll these gaps

Payment or series of payments upon approval or other potential milestones

The developer would receive an exclusivity extension for another product or would be able to sell it to another company

Constantly evolving bacteria

Resistance di�cult to predict

Complex clinical trials

Need to adapt regulatory pathways

Low awareness about appropriate use

Novel antibiotics are undervalued

Lack of availability of diagnostics

Over-prescription

Growing resistance in hospitals

Challenges ofappropriate

use

WHY NEW INCENTIVES ARE NEEDED TO DEVELOP ANTIBIOTICS

1

2

Challenges in scienti�c research

3 3

https://www.ifpma.org/resource-centre/ifpma-infographic-ifpma-members-antibacterial-compounds-pipeline-inventory-2015/

1 https://ec.europa.eu/health/am-r/sites/amr/�les/amr_summa-ry_action_plan_2017_en.pdf

2 http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Executive-Summary-Jan2018.pdf

3 https://www.ifpma.org/wp-content/uploads/2017/01/IFPMA_AMR_Policy_Position_January_2017_FINAL.pdf

4

3,4 44

AMRpipeline

NEUROLOGICAL DISORDERS

pipeline

1329 compounds62 compounds

PULLINCENTIVES

Collaboration between all stakeholders